Literature DB >> 16768642

Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.

James J McGough1, Keith McBurnett, Oscar Bukstein, Timothy E Wilens, Laurence Greenhill, Marc Lerner, Mark Stein.   

Abstract

This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS methylphenidate (MPH) (18-72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16768642     DOI： 10.1089/cap.2006.16.351

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN： 1044-5463            Impact factor:   2.576


  15 in total

Review 1.  Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis.

Authors:  Cellina Ching; Guy D Eslick; Alison S Poulton
Journal:  JAMA Pediatr       Date:  2019-07-01       Impact factor: 16.193

2.  Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Authors:  Liang Li; Yaning Wang; Ramana S Uppoor; Mehul U Mehta; Tiffany Farchione; Mitchell V Mathis; Hao Zhu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-18       Impact factor: 2.745

Review 3.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 4.  Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours.

Authors:  Milan T Makale; Carrie R McDonald; Jona A Hattangadi-Gluth; Santosh Kesari
Journal:  Nat Rev Neurol       Date:  2016-12-16       Impact factor: 42.937

Review 5.  Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Authors:  Gary Stiefel; Frank M C Besag
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

6.  Adolescent and caregiver reports of ADHD symptoms among inner-city youth: agreement, perceived need for treatment, and behavioral correlates.

Authors:  Aaron Hogue; Sarah Dauber; Emily Lichvar; Gabi Spiewak
Journal:  J Atten Disord       Date:  2012-04-27       Impact factor: 3.256

7.  Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.

Authors:  Joseph Gonzalez-Heydrich; Jane Whitney; Deborah Waber; Peter Forbes; Olivia Hsin; Stephen V Faraone; Alice Dodds; Sneha Rao; Christine Mrakotsky; Carlene Macmillan; David R Demaso; Carl de Moor; Alcy Torres; Blaise Bourgeois; Joseph Biederman
Journal:  Epilepsy Behav       Date:  2010-05-21       Impact factor: 2.937

8.  Clinical Strategies for Integrating Medication Interventions Into Behavioral Treatment for Adolescent ADHD: The Medication Integration Protocol.

Authors:  Aaron Hogue; Molly Bobek; Gregory Z Tau; Frances R Levin
Journal:  Child Fam Behav Ther       Date:  2014-10-01

9.  An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

Authors:  Paul Hammerness; Anna Georgiopoulos; Robert L Doyle; Linsey Utzinger; Mary Schillinger; Marykate Martelon; Kerry Brodziak; Joseph Biederman; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

10.  Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Authors:  Josep Antoni Ramos-Quiroga; Rosa Bosch; Xavier Castells; Sergi Valero; Mariana Nogueira; Nuria Gómez; Silvia Yelmo; Marc Ferrer; Yolanda Martínez; Miguel Casas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.